Below are the most recent publications written about "Neoplasm, Residual" by people in Profiles.
-
Zweegman S, Facon T, Hungria V, Bahlis NJ, Venner CP, Braunstein M, Pour L, Marti J, Basu S, Cohen YC, Matsumoto M, Suzuki K, Hulin C, Grosicki S, Legiec W, Beksac M, Maiolino A, Takamatsu H, Perrot A, Turgut M, Liu W, Wang J, van Brummelen E, Krevvata M, Lopez-Masi L, Carey J, Borgsten F, Rowe M, Carson R, Usmani SZ. Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS. Blood Adv. 2026 08 25; 10(16):5594-5606.
-
Moiseenko F, Stroyakovskiy D, Levchenko E, Fedyanin M, Gabina A, Oganesian A, Belukhin S, Stepanova M, Stepanova E, Artemyeva E, Myslik A, Volkov N, Bogdanov A, Shuginova T, Kryukov K, Kheinshtein V, Allakhverdiev A, Zaberegniy I, Akhmadiyarova Y, Popov M, Danilova A, Sehniaidze D, Savelov N, Levchenko N, Slugin E, Lopushanskaya O, Kuligina E, Aleksakhina S, Iyevleva A, Ivantsov A, Moiseyenko V, Imyanitov E. Surgical Removal of Residual Tumor Masses in Patients Undergoing Targeted Therapy for EGFR-Mutated Locally Advanced or Metastatic Lung Cancer. Int J Cancer. 2026 Nov 01; 159(9):2244-2261.
-
Suzuki K, Matsumoto M, Takamatsu H, Kosugi H, Kondo T, Fujisaki T, Facon T, Zweegman S, Ito M, Sakai C, Kanai S, Nakatogawa T, Rowe M, Carson R, Usmani SZ. Daratumumab plus VRd in Japanese transplant-ineligible/deferred NDMM patients: Japanese subgroup of the CEPHEUS trial. Int J Hematol. 2026 Jul; 124(1):104-113.
-
Mittal K, Mouw KW, Singh P. Circulating Tumor DNA in Urothelial Cancer: Practical Applications in Oncology Clinic. JCO Oncol Pract. 2026 Sep; 22(9):1508-1516.
-
Connolly JG, McCullum JC, Munroe C, Gaetani RS, Bliggenstorfer JT, Saraidaridis JT, Kuhnen AH, Marcello PW, Kleiman DA, Abelson JS. Circumferential Rectal Cancer Is a Risk Factor for Stricture Formation and Restaging Uncertainties After Neoadjuvant Therapy. Dis Colon Rectum. 2026 02 01; 69(2):181-190.
-
Firestone RS, Simhal AK, McAvoy D, Jurgens EM, Garcés JJ, Nemirovsky D, Derkach A, Maclachlan KH, Hultcrantz M, Mailankody S, Shah UA, Tan CR, Korde N, Hassoun H, Rajeeve S, Hashmi H, Landau HJ, Scordo M, Shah GL, Giralt SA, Diamond BT, Maura F, Hosszu K, Chung DJ, Landgren O, Usmani SZ, Lesokhin AM. Immune MRD Status Informs Tumor MRD Outcome Prognostication in Patients with Multiple Myeloma on Lenalidomide Maintenance. Clin Cancer Res. 2025 Nov 03; 31(21):4446-4456.
-
Gregory WM, Prior TJ, Bartlett JB, Sonneveld P, Dimopoulos MA, Moreau P, Usmani S, Facon T. Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential. Clin Cancer Res. 2025 Jun 03; 31(11):2154-2161.
-
Bhutani M, Robinson M, Foureau D, Atrash S, Paul B, Guo F, Grayson JM, Ivanina-Foureau A, Pineda-Roman M, Varga C, Friend R, Ferreri CJ, Begic X, Norek S, Drennan T, Anderson MB, Symanowski JT, Voorhees PM, Usmani SZ. MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma. Blood Adv. 2025 Feb 11; 9(3):507-519.
-
Usmani SZ, Facon T, Hungria V, Bahlis NJ, Venner CP, Braunstein M, Pour L, Martí JM, Basu S, Cohen YC, Matsumoto M, Suzuki K, Hulin C, Grosicki S, Legiec W, Beksac M, Maiolino A, Takamatsu H, Perrot A, Turgut M, Ahmadi T, Liu W, Wang J, Chastain K, Vermeulen J, Krevvata M, Lopez-Masi L, Carey J, Rowe M, Carson R, Zweegman S. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. Nat Med. 2025 Apr; 31(4):1195-1202.
-
Zhang Y, Guan Y, Xiao X, Xu S, Zhu S, Cao D, Yu M, Peng P, Wang J, Wang Y, Yin R, Guo J, Gao W, Li P, Bai J, Gong Y, Xia X, Yi X, Yang L, Xiang Y. Circulating tumor DNA detection improves relapse prediction in epithelial ovarian cancer. BMC Cancer. 2024 Dec 22; 24(1):1565.